Aurobindo’s CuraTeQ to Expand Manufacturing Operations via New $37M Facility

India-based Aurobindo Pharma’s subsidiary CuraTeQ Biologics plans to expand its operations by building an additional mammalian cell culture manufacturing facility and getting into the contract manufacturing business, the company said in a public filing.

The company said it plans to enter contract manufacturing operations (CMO) for biologicals, as well as seeking out other customers that need CMO services.

The goal is “effective utilization of capacities and augmenting the business prospects in this area,” said Aurobindo, adding that demand for global biologics contract manufacturing is growing at an 8 to 10 percent rate.

The company said it expects to spend around $37 million on the expansion. The facility is likely to be fully operational by fiscal year 2026, Aurobindo added.